男性接种四价HPV疫苗的药物经济学评价综述

• 药物经济学 • 上一篇

男性接种四价HPV疫苗的药物经济学评价综述

张诗雨,马爱霞

中国药科大学,中国药科大学

收稿日期:2018-03-17 修回日期:2018-03-17 出版日期:2018-06-25 发布日期:2018-06-25

Review of Pharmacoeconomic Evaluations of Quadrivalent HPV Vaccination for Males

ZHANG Shiyu and

China Pharmaceutical University,

Received:2018-03-17 Revised:2018-03-17 Online:2018-06-25 Published:2018-06-25

摘要/Abstract

摘要： 目的：对男性纳入四价HPV疫苗接种范畴的药物经济学评价进行分析，为我国是否应推荐男性接种HPV疫苗提供参考，也为未来开展相关药物经济学评价提供借鉴。方法：在PubMed，EMBASE，Web of Science，CNKI，万方等数据库进行检索，筛选相关文章，对其模型、结果进行总结分析。结果：我国目前HPV疫苗相关药物经济学分析还只局限于对二价HPV疫苗预防宫颈癌的分析，而国外对于是否应将男性纳入HPV疫苗免费接种范畴还存在争议。结论：我国需要开展四价HPV疫苗的药物经济学评价，并分析男性接种HPV疫苗是否经济，从而为决策制定提供证据支持。

Abstract: Objective： We analyzed pharmacoeconomic evaluations of quadrivalent HPV vaccination for males， in order to provide recommendation about if China should include males as HPV vaccine target population， and set basis for future implementation of related pharmacoeconomic evaluations. Methods： We searched for literature from PubMed， EMBASE， Web of Science， CNKI， and Wanfang， summarizing the model structures and results. Results： HPV vaccine related pharmacoeconomic evaluations in China are limited to analysis for bivalent HPV vaccine in preventing cervix cancer. Among foreign literature， there is no consensus about if males should be included in HPV vaccine program. Conclusion： It′s necessary for China to conduct pharmacoeconomic evaluations of quadrivalent HPV vaccination for males and analyze if it is cost-effective， so as to provide evidence for decision making.

张诗雨,马爱霞. 男性接种四价HPV疫苗的药物经济学评价综述[J]. .

ZHANG Shiyu and. Review of Pharmacoeconomic Evaluations of Quadrivalent HPV Vaccination for Males[J]. .

参考文献

[1] 邹华春. 应在青少年男男性行为人群中推广人乳头瘤病毒疫苗 [J]. 中华流行病学杂志, 2014, 9(35):
[2] PEARSON A L, KVIZHINADZE G, WILSON N, et al. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program [J]. BMC infectious diseases, 2014, 14(351.
[3] 陈蕊. 利用Markov模型对宫颈癌筛查方案的卫生经济学评价研究与应用 [D]; 华南理工大学, 2015.
[4] 刘怡君. HPV-16/18预防性疫苗的接种年龄对其预防子宫颈癌作用的卫生经济学研究 [D]; 大连医科大学, 2015.
[5] AUDISIO R A, ICARDI G, ISIDORI A M, et al. Public health value of universal HPV vaccination [J]. Crit Rev Oncol Hematol, 2016, 97(157-67.
[6] DE KOK I M, HABBEMA J D, VAN ROSMALEN J, et al. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? [J]. European journal of cancer (Oxford, England : 1990), 2011, 47(3): 428-35.
[7] DE MARTEL C, PLUMMER M, VIGNAT J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type [J]. International journal of cancer, 2017, 141(4): 664-70.
[8] LOWY D R, SCHILLER J T. Reducing HPV-associated cancer globally [J]. Cancer prevention research (Philadelphia, Pa), 2012, 5(1): 18-23.
[9] SHAPIRO G K, GUICHON J, PRUE G, et al. A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada [J]. Prev Med, 2017, 100(123-31.
[10] 达振强. 宫颈癌筛查方法评价及疾病负担系列研究 [D]; 兰州大学, 2011.
[11] 陈慧, 周思园, 孙振球. 常见妇科三大恶性肿瘤的流行及疾病负担研究现状 [J]. 中国现代医学杂志, 2015, 06): 108-12.
[12] CP C, 宿爱琴. 外阴癌:流行病学与发病机理 [J]. 国外医学妇产科学分册, 1993, 01): 31-3.
[13] 谢幸. 外阴癌的流行病学 [J]. 国外医学妇产科学分册, 1986, 03): 172-3.
[14] 张荣, 张轶清. 外阴癌治疗的研究进展 [J]. 中国医药指南, 2013, 03): 472-4.
[15] 胡凤玲. 人乳头状病毒(HPV)与口咽癌相关性的研究进展 [J]. 复旦学报：医学版, 2013, 40(4):
[16] 高广周, 朱琳, 赵晓航. 人乳头瘤病毒感染与口咽癌研究进展 [J]. 中华肿瘤防治杂志, 2014, 06): 481-4.
[17] 金晶, 王绿化. 同步放化疗治疗肛门癌 [J]. 癌症进展, 2007, 03): 260-8+59.
[18] 尖锐湿疣临床诊疗与防治指南(一) [J]. 中国艾滋病性病, 2015, 02): 172-4.
[19] 莫秀婷. 我国宫颈癌预防策略的经济学评价 [D]; 山东大学, 2015.
[20] 孙雨欣, 刘永军, 刘通. 宫颈癌疫苗用于18～25岁中国女性预防宫颈癌的药物经济学评价 [J]. 中国循证医学杂志, 2017, 01): 102-7.
[21] 张倩. 子宫颈癌筛查的风险分流及疫苗的卫生经济学评价研究 [D]; 北京协和医学院, 2017.
[22] BEN HADJ YAHIA M B, JOUIN-BORTOLOTTI A, DERVAUX B. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies [J]. Clin Drug Investig, 2015, 35(8): 471-85.
[23] TAIRA A V, NEUKERMANS C P, SANDERS G D. Evaluating human papillomavirus vaccination programs [J]. Emerg Infect Dis, 2004, 10(11): 1915-23.
[24] KULASINGAM S, CONNELLY L, CONWAY E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program [J]. Sex Health, 2007, 4(3): 165-75.
[25] ZECHMEISTER I, BLASIO B F, GARNETT G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria [J]. Vaccine, 2009, 27(37): 5133-41.
[26] ELBASHA E H, DASBACH E J, INSINGA R P. Model for assessing human papillomavirus vaccination strategies [J]. Emerg Infect Dis, 2007, 13(1): 28-41.
[27] OLSEN J, JEPSEN M R. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark [J]. Int J Technol Assess Health Care, 2010, 26(2): 183-91.
[28] CHESSON H W, EKWUEME D U, SARAIYA M, et al. The cost-effectiveness of male HPV vaccination in the United States [J]. Vaccine, 2011, 29(46): 8443-50.
[29] KIM J J. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis [J]. The Lancet Infectious diseases, 2010, 10(12): 845-52.
[30] GARLAND S M. Prevention strategies against human papillomavirus in males [J]. Gynecol Oncol, 2010, 117(2 Suppl): S20-5.